R
R

Roche

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Test makers target monkeypox market as cases surge

By Natalie Grover LONDON, June 3 (Reuters) - Diagnostic companies are racing to develop tests for monkeypox, hoping to tap into a new market as governments ramp up efforts to trace the world's first major outbreak of the viral infection outside of Africa. The scramble started last month, much like early 2020 when companies rushed to make kits to help diagnose COVID-19, creating a multibillion-dollar boon for test makers.
A
R
Q

European shares retreat from pre-war levels as investors hit pause

* STOXX 600 declines for first time in four days * Commodity-linked sectors outperform * Belgium's Kinepolis slips as finance chief exits * Cracks widen in EZ economy as war rages on By Shreyashi Sanyal and Anisha Sircar March 30 (Reuters) - European shares retreated after three straight sessions of gains on Wednesday, as investors paused to take stock of the outcome of Russia-Ukraine peace talks.
R
E
F
U
G

European shares fall after three days of gains as Roche weighs

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) March 30 (Reuters) - European shares fell on Wednesday, pulled lower by Swiss drugmaker Roche, with the STOXX 600 index retreating after three straight sessions of cautious gains that were driven by hopes of a breakthrough in Russia-Ukraine peace talks.
R
E
F
U
G

Scandal-hit Credit Suisse shakes up board with Schwan exit

By Silke Koltrowitz ZURICH, March 21 (Reuters) - Credit Suisse shook up its board on Monday, including the departure of its influential vice chair Severin Schwan, as it attempts to draw a line under a series of damaging scandals. Switzerland's second largest bank said that Schwan, 54, who was its lead independent director as well as chief executive of Roche ROG.S , would not stand for re-election to the board of directors at Credit Suisse's annual general meeting on April 29. Schwan faced critic
C
R
U

Credit Suisse vice chair faces re-election opposition -FT

ZURICH, Feb 9 (Reuters) - Credit Suisse CSGN.S Vice Chair Severin Schwan will face opposition from some major shareholders if he stands for re-election to the board of the embattled Swiss bank in April, the Financial Times reported on Wednesday. The FT said the investors were concerned about Schwan leading pharmaceuticals and diagnostics group Roche ROG.S , where he is chief executive, while at the same time acting as the vice-chair of Switzerland's second largest bank.
C
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.